Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the frequency of partial tandem duplication of ALL1 (MLL) in patients with acute myeloid leukemia (AML).
* Determine the predictive value of partial tandem duplication of ALL1 to identify a subset of AML patients who have a short duration of complete remission.
OUTLINE: All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected.
Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1.
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Prior registration on protocol CALGB-9665
Diagnosed with acute myeloid leukemia (AML)
Treated on a CALGB AML treatment protocol
Diagnostic bone marrow or blood specimen available
PATIENT CHARACTERISTICS:
Age:
15 and over
Clareo Health | Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
